Vitiligo: Mechanistic Insights Lead to Novel Treatments
| dc.contributor.author | Frisoli, Michael L. | |
| dc.contributor.author | Harris, John E. | |
| dc.date | 2022-08-11T08:09:19.000 | |
| dc.date.accessioned | 2022-08-23T16:26:35Z | |
| dc.date.available | 2022-08-23T16:26:35Z | |
| dc.date.issued | 2017-08-01 | |
| dc.date.submitted | 2017-08-29 | |
| dc.identifier.citation | J Allergy Clin Immunol. 2017 Sep;140(3):654-662. doi: 10.1016/j.jaci.2017.07.011. Epub 2017 Aug 1. <a href="https://doi.org/10.1016/j.jaci.2017.07.011">Link to article on publisher's site</a> | |
| dc.identifier.issn | 0091-6749 (Linking) | |
| dc.identifier.doi | 10.1016/j.jaci.2017.07.011 | |
| dc.identifier.pmid | 28778794 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/36597 | |
| dc.description.abstract | Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting the regeneration of melanocytes. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies, their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments. | |
| dc.language.iso | en_US | |
| dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28778794&dopt=Abstract">Link to Article in PubMed</a> | |
| dc.relation.url | https://doi.org/10.1016/j.jaci.2017.07.011 | |
| dc.subject | Allergy and Immunology | |
| dc.subject | Cellular and Molecular Physiology | |
| dc.subject | Dermatology | |
| dc.subject | Immune System Diseases | |
| dc.subject | Skin and Connective Tissue Diseases | |
| dc.title | Vitiligo: Mechanistic Insights Lead to Novel Treatments | |
| dc.type | Journal Article | |
| dc.source.journaltitle | The Journal of allergy and clinical immunology | |
| dc.source.volume | 140 | |
| dc.source.issue | 3 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/metnet_pubs/117 | |
| dc.identifier.contextkey | 10678108 | |
| html.description.abstract | <p>Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting the regeneration of melanocytes. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies, their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments.</p> | |
| dc.identifier.submissionpath | metnet_pubs/117 | |
| dc.contributor.department | UMass Metabolic Network | |
| dc.contributor.department | Graduate School of Biomedical Sciences, MD/PhD Program | |
| dc.contributor.department | Graduate School of Biomedical Sciences, Immunology and Microbiology Program | |
| dc.contributor.department | Department of Dermatology | |
| dc.source.pages | 654-662 |
Files in this item
Name:
Publisher version